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Carcinogenicity of Chlorinated Methane and
Ethane Compounds Administered in
Drinking Water to Mice
by James E. Klaunig,* Randall J. Ruch,* and
Michael A. Pereirat
The chlorinated hydrocarbons chloroform (CHC13), 1,1-dichlorethane (1,1-DCE) and 1,2-dichloroethane
(1,2-DCE) have been detected in finished drinking water. When administered to B6C3F1 mice by gavage
in corn oil, these compounds have been shown to induce hepatic tumors. The present study examines the
effect on liver tumor incidence ofcontinuous treatment ofCHC13 (600 mg/L and 1800 mg/L), 1,1-DCE (835
mg/L and 2500 mg/L), and 1,2-DCE (835 mg/L and 2500 mg/L) administered in drinking water to male
B6C3F1 mice using a two-stage (initiation/promotion) treatment protocol. Seventy 4-week-old male
B6C3F1 mice constituted each treatment group. Of these mice, 35 were initiated by treatment with di-
ethylnitrosamine (DENA) (10mg/L) inthedrinkingwaterfor4weeks. Theremaining35receiveddeionized
drinking water. Each group was subsequently treated with one oftwo concentrations ofCHC13, 1,1-DCE,
or 1,2-DCE in drinking water for 52 weeks. An additional group received phenobarbital (PB) (500 mg/L)
and served as the positive control for liver tumor promotion. Mice were sampled after 24 weeks (10 mice)
and52weeks (25mice). Atsampling, liverandlungtumorsweredetected. Noneofthecompoundsincreased
the number or incidence oflung or liver tumors by themselves. PB promoted liver tumor formation (but
not lungtumors) inthe DENA- initiated mice. 1,1-DCE and1,2-DCE didnotaffectthe incidenceornumber
of liver or lung tumors in the DENA-initiated animals. CHC13, however, inhibited liver and lung tumor-
igenesis in the DENA-initiated mice.
Introduction
Chloroform (CHC13), 1,1-dichloroethane (1,1-DCE),
and 1,2-dichloroethane (1,2-DCE) have been detected
infinisheddrinkingwater(1). Thesecompoundsinduced
neoplasms in Osborne-Mendel rats and B6C3F1 hybrid
mice when administered chronically by daily gavage.
Chloroform produced kidney-epithellal tumors in rats
and ahighincidenceofhepatocellularcarcinomas inmice
(2). 1,2-DCE treatment caused stomach-squamous cell
carcinomasinratsandhepatocellularcarcinomasinmice
(2). 1,1-DCE exposure induced hepatocellular carcino-
mas in mice and a slight increase in thyroid tumors in
rats (2). Therefore, these three compounds, when ad-
ministered chronically to B6C3F1 mice by daily gavage
(in a corn oil vehicle), have been shown to induce he-
patocellular neoplasms (2). The hepatocarcinogenicity
of these compounds administered in drinking water to
mice has, however, not been established. CHC13 and
1,1-DCE appear to be nongenotoxic, producing their
carcinogenic effects through epigeneticmechanisms (3).
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1,2-DCE has been shown to be mutagenic (4) and ca-
pable ofbinding to cellularmacromolecules (5) and thus
probably functions through genotoxic mechanisms.
The present study was undertaken to examine the
carcinogenicity ofCHC13, 1,1-DCE, and 1,2-DCE when
chronicallyadministeredto B6C3F1 male miceindrink-
ing water, using a two-stage carcinogenesis protocol to
determine if CHC13, 1,1-DCE, and 1,2-DCE may be
expressing their hepatocarcinogenicity through tumor
promotion mechanisms.
Materials and Methods
Chemicals
Diethylnitrosamine (DENA) and sodium phenobar-
bital (PB) were purchased from Sigma Chemical Co.
(St. Louis, MO). CHCl3, 1,1-DCE, and 1,2-DCE (glass-
distilled, no preservatives), were purchased from Bur-
dick and Jackson Laboratories, Inc. (Muskegon, MI).
Animals
Male C3H mice (8 weeks old) and female C57BL mice
(8 weeks old) were purchased from Charles River
Breeding Labs (Wilmington, MA). These mice wereKLAUNIG, RUCH, AND PEREIRA
Table 1. Experimental design.
Treatment
Group Initiationa Promotion"
1 _
2 Phenobarbital
3 +
4 + Phenobarbital
5 CHCl8 (low dose)
6 + CHC13 (low dose)
7 CHC13 (high dose)
8 + CHC13 (high dose)
9 1,1-DCE (low dose)
10 + 1,J-DCE (low dose)
11 1,J-DCE (high dose)
12 + 1,1-DCE (high dose)
13 1,2-DCE (low dose)
14 + 1,2-DCE (low dose)
15 1,2-DCE (high dose)
16 + 1,2-DCE (high dose)
aFor tumor initation, DENA was placed in drinking water (10 mg/
L) for 4 weeks (+ indicates DENA was present in drinking water;
- indicates untreated deionized drinking water was present).
bFor tumor promotion, compounds were placed in the drining
water until sacrifice (at 24 or 52 weeks' exposure). Concentrations
used included PB, 500 mg/L; CHC13, low dose, 600 mg/L; CHC13 high
dose, 1800 mg/L; 1,1-DCE, low dose, 835 mg/L; 1,1-DCE, high dose,
2500 mg/L; 1,2-DCE, low dose, 835 mg/L; and 1,2-DCE, high dose,
2500 mg/L (-indicates that untreated, deionized drinkingwaterwas
present).
bred at the Medical College of Ohio animal facility to
produce B6C3F1 hybrid mice, which were used in sub-
sequent experiments. All mice were maintained inplas-
tic cages with corncob bedding and given certified Pur-
ina Laboratory Chow and water ad libitum. Male
B6C3F1 hybrid mice were weaned at30days ofage and
treated as noted below.
Experimental Design
Thirty-day-old male hybrid mice were randomly
placed into 16 groups of35 mice each. The design ofthe
study is shown in Table 1. Eight ofthe groups received
drinkingwatercontainingDENA(10mg/L)for4weeks.
Theremainingeight groupsreceived deionized drinking
water. The DENA-treated animals constituted the in-
itiated groups, and the deionized-drinking-water-
treated animals constituted the noninitiated groups.
After4weeks, theeightinitiated groupsreceiveddrink-
ing watercontainingeither deionized wateralone orPB
(500 mg/L), CHC13 (600 mg/L; low dose), CHCl3 (1800
mg/L; high dose), 1,1-DCE (835 mg/L; low dose), 1,1-
DCE (2500 mg/L; high dose), 1,2-DCE (835 mg/L; low
dose), or 1,2-DCE (2500 mg/L; high dose). Similarly,
the eight noninitiated groups received drinking water
containing either deionized water or PB, high-dose
CHCl3, low-dose CHCl3, high-dose 1,1-DCE, low-dose
1,1-DCE, high-dose 1,2-DCE, or low-dose 1,2-DCE.
All compounds were added to deionized/distilled
water and placed in amber glass drinking water bottles
containing Teflon stoppers and double sipper tubes.
Mice were sacrificed after 24 weeks or 52 weeks of pro-
motion. Ten mice were sacrificed at the 24-week sam-
pling time, and the remaining 25 were sacrificed at the
52-week sampling time. At sacrifice, complete necrop-
sieswere conducted oneachmouse, andalltissueswere
examined for the presence of gross pathologic lesions.
Liver, lungs, and kidneys were weighed, fixed in 10%
phosphate-buffered formalin, and processed for routine
hematoxylin and eosin (H&E) slide preparation. His-
tologic sections of liver, kidneys, and lungs from each
mouse were examined, and the number oftumors were
quantitated.
Drinking water was freshly made and changed
weekly, and its consumption was monitored weekly for
each cage. Intake was calculated by weighing water
bottles before and after each weeklywaterchange. The
mean water intake (in grams) of each mouse per day
was calculated by subtractingthe weight ofwater after
1 week from the weight of the water at time ofifiling
and dividing this number by the number of days and
the number of mice per cage. Body weights of mice
during the treatment process were determined on a
monthly basis for each cage.
Dose levels of CHCl3, 1,1-DCE, and 1,2-DCE used
in the present studywere chosenthrough apreliminary
toxicity study. Maximum tolerated dose (MTD) drink-
ingwaterlevels ofCHC13, 1,1-DCE, and 1,2-DCE were
1800 mg/L, 2500 mg/L, and 2500 mg/L, respectively.
The MTD was the highest concentration of compound
that failed to cause mortality in 8-week-old male
B6C3F1 mice after a 4-week exposure period. For the
subsequent long-term treatment studies, MTD and 1/3
MTD were used as the dose levels. Dose levels for
DENA of10 mg/L and PB (500mg/L) were determined
through previous studies in our laboratory.
Results
Body Weight and Drinking Water Intake
Body weight determinations made during the treat-
ment period are shown in Figure 1. Untreated mice
displayed a steady increase in body weight over time.
Alltreated mice displayed meanbodyweightgainsthat
paralleledthoseofthecontrolmicebutwerelower. Only
mice receiving DENA and CHC13 (low dose), DENA
and CHC13 (high dose), and CHC13 (high dose) by itself
exhibited a statistically significant (p < 0.05) decrease
in mean body weight from that of the untreated mice
from 8 weeks to 56 weeks oftreatment.
The pattern ofdrinkingwaterintake in the mice dur-
ing the treatment times paralleled that of the body
weight determinations (Fig. 2). Mice receiving CHC13
(both high and low doses; with and without DENA ini-
tiation) and 1,2-DCE (high doses; with and without
DENA initiation) displayed a statistically significant (p
< 0.05) decrease in drinking water intake at all times
sampled from 8 weeks until 48 weeks oftreatment over
that ofthe other treatment groups.
Survival
All untreated, PB-treated, DENA-untreated, and
DENA-PB-treated mice survived until the 52-week
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FIGURE 1. Mean body weights ofmice (in grams) sampled after weaning until sacrifice at week 56: (a) mean body weight per mouse of groups
receiving deionized water only, DENA only, PB only, and DENA + PB; (b) body weights ofmice that received high- and low-dose CHCl8
with and without prior DENA initiation; (c) body weights of mice that received 1,1-DCE (high and low dose) with and without DENA
treatment; (d) mean body weights of mice that received 1,2-DCE (high and low dose) with and without DENA treatment.
samplingtime. Death occurred inweek40to 52 oftreat-
ment in mice treated with DENA-CHC13 (high dose) (4
mice), DENA-CHC13 (low dose) (3 mice), CHC13 (high
dose) (3 mice), CHCl3 (low dose) (2 mice) and DENA-
1,2-DCE (high dose) (3 mice). These mice were necrop-
sied, and the findings were included with the liver and
lung tumor data at the 52-week sampling time.
Liver Tumors
Liver tumors detected in the sampled mice included
adenomas and carcinomas. The liver tumor incidence in
treated and control mice reflects the total number of
tumors (adenomas and carcinomas) found by histologic
examination (Table 2). Untreated male B6C3F1 mice
exhibited no livertumors atthe24-weeksamplingtime.
However, at 52 weeks, 5 of25 mice were found to have
livertumors, with an average of0.08tumors per mouse.
Treatment with CHCl3, 1,2-DCE, or 1,1-DCE (both
high and low doses) without initiation resulted in no
significant increase or decrease either in liver tumor
incidence orinthe number oftumors perliverfromthat
of the untreated control mice at either sampling time.
Phenobarbital exposure without initiation, however,
produced a significant increase in both liver tumor in-
cidence andthe meannumberoflivertumors per mouse
over that ofthe untreated controls at both the 24-week
and the 52-week sampling times.
Mice initiated with DENA for 4 weeks followed by
treatment with deionized drinking water exhibited a
70% liver tumor incidence with a mean number of 3.0
tumors per liver at the 24-week sampling time and a
100% liver tumor incidence with a mean of29.3 tumors
per liver at the 52-week samplingperiod. Miceinitiated
with DENA followed by exposure to PB in drinkdng
water displayed a significant increase over that of the
DENA-initiated mice in both the incidence of liver tu-
mors at the 24-week sampling time and in the mean
number of liver tumors at both the 24-week and 52-
week sampling times. Mice initiated with DENA fol-
lowed by promotion with either 1,1-DCE or 1,2-DCE
at both high and low dose levels exhibited no significant
difference in liver tumor incidence or mean liver tumor
number at either of the two sampling times. CHCl3
administered at both low and high dose levels in the
drinking water following DENA initiation produced a
significant decrease in the mean number ofliver tumors
per mouse from that ofthe group initiated with DENA
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FIGURE 2. Average drinking water intake (in grams), for each mouse per day sampled from 4 weeks post-weaning until 4 weeks before
sacrifice: (a) B6C3F1 male mice treated with water only, PB only, DENA initiation, and DENA + PB; (b) DENA-initiated and -noninitiated
mice subsequently treated with CHCl3 (high and low dose); (c) mice that received 1,1-DCE (high or low dose) with or without DENA
initiation for 4 weeks; (d) mice that received 1,2-DCE (high or low dose) subsequent to DENA or no treatment.
and administered deionized drinking water at both the tumors per mousewhencompared tomiceinitiatedwith
24-week and 52-week sampling period. DENA and administered deionized drinking water.
Lung Tumors
Lung tumors were also detected in treated mice.
When examined histologically, all lung tumors proved
to be lung adenomas. No significant differences in lung
tumor incidence or in the mean number oflung tumors
per mouse was found in noninitiated mice receiving
either chlorofonn, 1,1-DCE, 1,2-DCE, or PB (Table 3).
Mice initiated with DENA displayed a significant in-
crease in lung tumor incidence and in the mean number
oflung tumors per mouse over that ofthe noninitiated
mice. However, mice treated with 1,1-DCE, 1,2-DCE,
CHC13, PB, or deionized water exhibited no significant
difference in either tumor incidence or the number of
Morphometric Determination of Liver
Tumor Area
Histologic examination of the CHCl3-treated mice
(both DENA-initiated and-noninitiated) suggestedthat
thelivertumorsintheCHCl3-treatedmice.were smaller
in size when compared to those of the other treated
mice. To quantitate this observation, tumors in CHC13-
treated mice (both DENA-initiated and -noninitiated at
both high and low dose) were measured using a com-
puterized planimetry system (6). The liver tumor area
and total liver area was quantitated in H&E-stained,
randomly selected liver sections from the 52-week
mouse sample. Similar measurements were made on
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Table 2. Liver tumor incidence.
Treatment 24 Weeks sampling time 52 Weeks sampling time
No. of tumors/ No. of tumors/
Initiation Promotion Incidence (%)a mouse (range) Incidence (%)a mouse (range)
0/10 (0) 0 5/25 (20) 0.08 ± 0.28 (0-2)
+ 7/10 (70) 3.00 ± 2.50 (0-8) 25/25 (100) 29.30 ± 15.40 (6-61)
- CHC13 (600 mg/L) 0/10 (0) 0 3/25 (12) 0.10 ± 0.30 (0-1)
+ CHCI3 (600 mg/L) 4/10 (40) 0.60 ± 0.84 (0-2) 25/25 (100) 19.40 ± 14.10 (1-44)
- CHC13 (1800 mg/L) 0/10 (0) 0 4/25 (16) 0.30 ± 0.90 (0-4)
+ CHC13 (1800 mg/L) 3/10 (30) 0.78 ± 1.20 (0-2) 20/25 (80) 18.40 ± 14.70 (0-49)
- 1,1-DCE (835 mg/L) 0/10 (0) 0 7/25 (28) 0.20 ± 0.40 (0-1)
+ 1,1-DCE (835 mg/L) 7/10 (70) 6.60 ± 8.70 (1-27) 25/25 (100) 38.33 ± 20.40 (6-67)
- 1,1-DCE (2500 mg/L) 0/10 (0) 0 2/25 (8) 0.10 + 0.40 (0-2)
+ 1,1-DCE (2500 mg/L) 6/10 (60) 2.80 ± 3.10 (2-8) 23/25 (92) 31.60 ± 34.70 (0-48)
- 1,2-DCE (835 mg/L) 0/10 (0) 0 4/25 (16) 0.20 ± 0.50 (0-2)
+ 1,2-DCE (835 mg/L) 8/10 (80) 5.60 ± 5.90 (1-17) 25/25 (100) 34.50 ± 17.40 (7-59)
- 1,2-DCE (2500 mg/L) 0/10 (0) 0 3/25 (12) 0.10 ± 0.30 (0-1)
+ 1,2-DCE (2500 mg/L) 3/10 (30) 0.90 ± 1.90 (1-6) 23/25 (92) 25.20 ± 16.70 (0-53)
- Phenobarbital (500 mg/L) 2/10 (20) 0.30 ± 0.67 (1-2) 9/25 (36) 0.70 ± 1.10 (0-3)
+ Phenobarbital (500 mg/L) 9/10 (90) 16.00 ± 17.10 (7-43) 25/25 (100) 42.80 ± 1.30 (9-60)
aIncidence values represent the number of mice with liver tumors per total number of mice sampled. The number of tumors per mouse
represents the mean ± SD of the number ofliver tumors per mouse for all mice in that group at that sampling time.
histologic sections from mice initiated with DENA and
administered deionized water, mice initiated with
DENAandpromoted withPB, anduntreatedmice sam-
pled at 52 weeks. Quantitation of the relative tumor
area and the mean area ofeach tumor is shown in Table
4.
Other Findings
In addition to lung and liver tumors, focal areas of
cellular necrosis were found in the kidneys and liver of
CHCl3-treated mice at the 24-week and 52-week sam-
pling times. No extratumorous necrosis was observed
in untreated, PB-treated, DENA-initiated, or DENA-
PB-treated mice. Occasional focal areas of hepatic ne-
crosis were seeninthehigh-dose, 1,2-DCE-treatedmice
(both initiated and noninitiated). Focal areas ofhepatic
lipid accumulation were seen in the CHC13-treated mice
(high dose). Focal areas of necrosis (one to two areas
per section) were observed in the kidney tubules of
CHC13-treated mice.
Discussion
In the present study, CHC13, 1,1-DCE, and 1,2-DCE
failed to induce hepatic tumors in male B6C3F1 mice
whenadministered for52weeksindrinkingwater. Sim-
ilarly, when these three chlorinated compounds were
evaluated forlivertumorpromotionactivity, theyfailed
to increase either the tumor incidence or the mean tu-
Table 3. Lung tumor incidence.
Treatment 24 Weeks sampling time 52 Weeks sampling time
No. of tumors/mouse No. of tumors/mouse
Initiation Promotion Incidence (%)a (range) Incidence (%)a (range)
- - 0/10 (0) 0 2/25 (8) 0.10 + 0.30 (0-1)
+ - 1/10 (10) 0.10 ± 0.30 (0-1) 18/25 (72) 1.40 + 1.40 (0-5)
- CHC13 (600 mg/L) 0/10 (0) 0 0/25 (0) 0
+ CHC13 (600 mg/L) 0/10 (0) 0 13/25 (52) 0.80 ± 0.90 (0-3)
- CHC13 (1800 mg/L) 0/10 (0) 0 0/25 (4) 0.04 ± 0.20 (0-1)
+ CHC13 (1800 mg/L) 1/10 (10) 0.10 ± 0.30 (0-1) 6/25 (24) 0.30 ± 0.60 (0-2)
- 1,1-DCE (835 mg/L) 0/10 (0) 0 0/25 (0) 0
+ 1,1-DCE (835 mg/L) 0/10 (0) 0 20/25 (80) 2.50 ± 2.60 (0-1)
- 1,1-DCE (2500 mg/L) 0/10 (0) 0 1/25 (4) 0.04 + 0.20 (0-1)
+ 1,1-DCE (2500 mg/L) 2/10 (20) 0.20 ± 0.40 (0-1) 20/25 (80) 1.80 ± 1.60 (0-6)
- 1,2-DCE (835 mg/L) 1/10 (10) 0.10 ± 0.30 (0-1) 1/25 (4) 0.04 ± 0.20 (0-1)
+ 1,2-DCE (835 mg/L) 2/10 (20) 0.20 ± 0.40 (0-1) 12/25 (48) 1.00 ± 1.10 (0-3)
- 1,2-DCE (2500 mg/L) 0/10 (0) 0 3/25 (12) 0.10 ± 0.30 (0-1)
+ 1,2-DCE (2500 mg/L) 0/10 (0) 0 23/25 (88) 2.60 ± 2.00 (0-9)
- Phenobarbital (500 mg/L) 0/10 (0) 0 0/25 (0) 0
+ Phenobarbital (500 mg/L) 1/10 (10) 0.10 ± 0.30 (0-1) 11/25 (44) 0.80 ± 1.00 (0-4)
aIncidence values represent the number of mice with lung tumors per total number of mice sampled. The number of tumors per mouse
represents the mean ± SD ofthe number oftumors per mouse for all mice sampled at the sampling time.
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Table 4. Morphometric measurement of liver tumor area.'
Relative liver Mean tumor
Initiation Promotion tumor area, % area, cm2
0.50 8.65
+ 12.10 12.82
+ Phenobarbital 22.31 16.37
(500 mg/L)
- CHCl3 (high dose) 6.21 9.78
+ CHCl3 (high dose) 9.27 9.54
- CHCl3 (low dose) 1.12 7.47
+ CHCl3 (low dose) 6.02 11.97
aValues were determined by quantitating theliver tumor area and
total liver area on randomly selected H&E-stained histologic sections
from mice sampled at 52weeks treatment. Measurements were made
using a computer-assisted planimetry (Altos computer with bitpad
and stereology software). The relative tumor area was determined
by using the equation: (liver tumor area/total liver area) x 100. The
mean tumor area was determined by using the equation: liver tumor
area/number of liver tumors.
mor number per mouse over that seen with DENA ini-
tiation alone. In fact, CHCl3, when administered in the
tumorpromotion protocol, significantlyinhibitedtheav-
erage number and average size of liver tumors com-
pared to those ofthe DENA-only-treated mice. Pheno-
barbital, a liver tumor promoter in mice and rats,
increased the mean number and mean size of the
DENA-initiated liver tumors.
The observed liver tumor findings with CHCl3, 1,1-
DCE, and 1,2-DCE are inoppositiontothosepreviously
reported (2) for these three compounds when adminis-
tered to male B6C3F1 mice by gavage. In this previous
study, CHCl3 (300 mg/kg), 1,1-DCE (3000 mg/kg), and
1,2-DCE (200 mg/kg), administered in corn oil by daily
gavage 5 times a week for 78 weeks, produced a sig-
nificant increase in the incidence of liver tumors (2).
Chloroform induced liver tumors in 44 out of 45 mice,
1,1-DCE induced liver tumors in 8 out of47 mice, and
1,2-DCE induced liver tumors in 12 out of47 mice (2).
The difference in the liver tumor response between the
corn oil gavage study and the present drinking water
study may be related to the method of treatment (ga-
vage vs. drinking water) and the vehicle (corn oil vs.
water) used for administration. Three potential reasons
forthese differences include: the dose indrinkingwater
may be lower than that given by the gavage protocol;
the uptake, distribution, and elimination of the com-
pounds associated withthetwomodesoftreatment may
vary; andthecorn oilvehiclemaybemodifyingthe liver
tumor response. With regard to dose in the mouse, in
the present study, the average water intake for a 24-
week-old mouse [mean body weight 30 g] given 1800
mg/L CHCl3 in drinking water was 4.3 g of water per
day. This amount is calculated as aweekly intake of1.8
mg ofCHCl3/g body weight ofmouse, which compares
favorablywith aweeklyintakeof1.5mg/gofchloroform
body weight when given by gavage (Table 5). When an
approximately weekly dose is calculated using this
method, it appears that for the high-dose CHCl3, the
doses are similar (1.8 mg/g body weight for drinking
watervs. 1.5mg/gbodyweightforgavage); forthehigh
Table 5. Comparison ofdose levels ofCHCI3, 1,1-DCE, and 1,2-
DCE in B6C3F1 mice.
Approximate
weekly dose,
mg/g body
Compound Modeoftreatment Dosea weight mouseb
CHC13 Drinking water 1800 mg/L 1.8
Corn oil gavage 300 mg/kg 1.5
1,1-DCE Drinking water 2500 mg/L 3.8
Corn oil gavage 3000 mg/kg 15.0
1,2-DCE Drinking water 2500 mg/L 3.3
Corn oil gavage 200 mg/kg 1.0
aCorn oil gavage dose from previous study (2) represents the max-
imumtolerated doseadministered dailyfivetimesperweek. Drinking
water dose taken from the present study.
bApproximate weekly dose calculated forthe drinldng water mode
oftreatment as follows: mean daily water uptake (mL) for30gmouse
x concentration in drinking water (mg/mL) x 7 days/30 g (mouse
body weight). Approximate weekly dose calculated for the corn oil
gavage mode of treatment as follows: mean daily dose (mg/g) for 30
g mouse x 5 treatments.
dose of 1,1-DCE, the corn oil gavage resulted in a 5-
fold higher dose than that of the drinking water; and
for the 1,2-DCE, the high dose in drinking water re-
sulted in a dose 3.3-fold higher than the gavage dose.
Therefore, with the exception of the 1,1-DCE, the
weeklydrinkingwaterdosesarehigherthantheweekly
gavage doses.
Whether the pharmacokinetics ofthe two treatments
are similar remains to be examined. In the present
study, focal kidney and liver necrosis was observed in
the chloroform-treated mice, suggesting that the chlo-
roform was getting to the liver and kidneys. However,
the relative amount ofcompound taken up by the liver
and kidneyusingthe twomodes ofadministration needs
furtherstudy. Thepossibilityofatumor-promotingrole
forthecornoilvehicleusedinthegavageadministration
of carcinogenic/toxic compounds has recently been
raised (7). Whether corn oil may modify the response
of the hepatocytes to chlorinated hydrocarbons also
needs to be examined.
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